A Complete Graphene Solutions Company
Monday – Friday

8 am – 5 pm

Contact Us

(613) 238-7417

945 Princess Street

Kingston ON. Canada

Grafoid Announces Reverse Takeover with Stria Lithium Inc.


KINGSTON, ONTARIO, October 5, 2020 – Grafoid Inc. (“GRAFOID” or the “Company”), a global leader in the graphene products and applications market, announced today that the Company has signed a letter of intent dated September 23, 2020 (the “LOI“) with Stria Lithium Inc. (“Stria”), which sets forth the general terms and conditions of a proposed business combination transaction that will result in a reverse takeover of Stria by Grafoid Shareholders (the “Acquisition“). 

Subject to the conditions set forth in the LOI, Stria and Grafoid will enter into a business combination transaction by way of a share exchange, amalgamation, arrangement or similar form of transaction, which will result in Grafoid becoming a wholly-owned subsidiary of Stria or otherwise combining its corporate existence with that of Stria.  The final structure of the Acquisition is subject to receipt of final tax, corporate and securities law advice for both Stria and Grafoid.  The successor reporting issuer corporation to Stria, after having combined its operations with Grafoid, whether or not Grafoid remains a separate subsidiary of Stria or the two corporations are formally combined, is referred to herein as the “Resulting Issuer” and common shares of the Resulting Issuer are referred to herein as the “Resulting Issuer Shares”. 

Prior to the closing of the Acquisition, (i) Stria will settle an outstanding debt totaling $500,000 by way of a shares-for-debt transaction pursuant to which Stria is expected to issue 25,000,000 Stria Shares at an issuance price of $0.02 per Stria Share (the “Stria Shares-for-Debt Transaction”) and (ii) Stria will complete a 25-for-1 share consolidation of the Stria Shares (the “Share Consolidation”).

Concurrent with the closing of the Acquisition, Stria will complete an equity financing of Resulting Issuer Shares on a post-Share Consolidation basis.

It is anticipated that the board of directors of Stria shall be re-structured to consist of up to 10 directors, 6 of which shall be a nominee of Grafoid.  Stria will take all necessary steps to ensure that upon closing, such nominees have been duly elected or appointed as directors of Stria. 

The Acquisition is subject to, among other details, mutual due diligence, approval of Grafoid Shareholders and approval of the new listing by the TSX-V as applicable, and standard closing conditions, including the conditions described herein.

The name of the Corporation will be changed in due course to a name that both parties agree to.

Completion of the transaction is subject to a number of conditions, including but not limited to, Exchange acceptance and if applicable, required shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Stria Lithium should be considered highly speculative. The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this news release.

Additionally, Stria also announced the resignations of Gary Economo and Lindsay Weatherdon from its board of directors effective September 24, 2020. Gary Economo has also resigned as President and CEO of Stria.  Jeffrey York, the Chairman of the Board of Stria Lithium, will act as the interim CEO and President until the close of the transaction.  Finally, Grafoid recently announced that Gary Economo resigned as CEO and from the Grafoid Board of Directors effective July 30, 2020 and Marc Roy was appointed as the CEO and to the Board of Directors of Grafoid effective August 3, 2020.

Overview of Grafoid Inc.

Founded in 2011, Grafoid Inc. is a graphene research, development and investment company that invests in, manages and develops markets for processes that produce economically scalable graphene for use in graphene development applications by leading corporations and institutions. Grafoid’s leading investment produces application friendly, minimal-defect, high-energy density few layer graphene, utilizing a safe, non-destructive extraction process, leaving the lowest possible ecological footprint. The completely unique, proprietary process results in what Grafoid regards as a new global standard for economically scalable, high-purity graphene products—that can be tailored to both industrial and commercial applications.

A more comprehensive news release will be issued by the Company in the near future disclosing details of the Acquisition, including financial information respecting Grafoid, the names and backgrounds of all persons who will constitute insiders of the Resulting Issuer, and information respecting sponsorship if required, once an agreement has been finalized and certain conditions have been met, including: satisfactory completion of due diligence and execution of the Definitive Agreement.

For more information about Grafoid, please visit www.grafoid.com.

About Stria Lithium

Stria Lithium is a Canadian junior mineral exploration company with an expanding technology focus and has a 100% interest in the Pontax spodumene lithium project in Northern Québec. 

Lithium is a critical metal in the universal fight against global warming.  It is a core component of Lithium-Ion batteries used for powering electric vehicles and for industrial scale energy storage.

For more information about Stria Lithium, please visit www.strialithium.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

About Grafoid

Founded in 2011, Grafoid Inc. is a graphene research, development and investment company that invests in, manages and develops markets for processes that produce economically scalable graphene for use in graphene development applications by leading corporations and institutions. Grafoid’s leading investment produces application friendly, minimal-defect, high-energy density few layer graphene, utilizing a safe, non-destructive extraction process, leaving the lowest possible ecological footprint. The completely unique, proprietary process results in what Grafoid regards as a new global standard for economically scalable, high-purity graphene products — trademarked under the MesoGraf™ trade name — that can be tailored to both industrial and commercial applications.

Investor Contact:

Scott Anderson

Investor Relations

Phone:  (858) 229-7063

Email:  sanderson@nextcap-ir.com

GRAFOID INC. ANNOUNCES APPOINTMENT OF MARC R. ROY AS CHIEF EXECUTIVE OFFICER


KINGSTON, ONTARIO, July 29, 2020 – Grafoid Inc. (“GRAFOID” or the “Company”), a global leader in the graphene products and applications market, announced today that it has appointed Marc R. Roy as Chief Executive Officer, effective August 3, 2020.  Mr. Roy will also join Grafoid’s Board of Directors effective August 3, 2020.

Mr. Roy brings to Grafoid more than 20 years of global experience in Executive Management roles.   Mr. Roy, age 54, most recently served as an Executive at BDA, Inc. overseeing EMEA as well as global mergers and acquisitions from January 2017 to June 2020.  Prior to his position at BDA, Inc., Mr. Roy served as CEO of BrandAlliance from May 2013 to January of 2017.  Prior to BrandAlliance, Marc served as CEO of Accolade Reaction Promotion Group from January 1999 to February 2010.  His extensive experience in mergers and acquisitions as well as a track record in delivering results, while leading transitioning companies, made him an ideal addition to the executive team and Board of Directors. 

“Marc possesses the leadership and breadth of business experience we believe are critical to lead Grafoid, including the proven ability to forge major client relationships, with an enhanced focus on leading through innovation,” said Mr. Jeffrey York, Chairman of the Board of Grafoid. “On behalf of the Board, we look forward to working with Marc in his new role as Grafoid enters into its next phase of development, including the growth and commercialization of the Company’s graphene-based products and applications.” 

“I am very pleased to have the opportunity to lead Grafoid at this time, as we enter into the essential phase of the Company’s development and advance commercialization of the products in our development pipeline,” said Mr. Roy. “With a strong development plan in place, I believe Grafoid has the potential to deliver significant shareholder value while positively contributing to the graphene industry.”

Gary Economo, outgoing President and CEO of Grafoid, commented, “I wish to thank the Board of Directors, management, employees and our dedicated shareholders for all of the support you have provided to me.  I remain confident in the great potential and future of Grafoid’s products in development and I believe this is the ideal time to allow Marc to continue the development of the product pipeline and move forward with plans to gain traction in the marketplace and commercialize product development.”

About Grafoid

Founded in 2011, Grafoid Inc. is a graphene research, development and investment company that invests in, manages and develops markets for processes that produce economically scalable graphene for use in graphene development applications by leading corporations and institutions. Grafoid’s leading investment produces application friendly, minimal-defect, high-energy density few layer graphene, utilizing a safe, non-destructive extraction process, leaving the lowest possible ecological footprint. The completely unique, proprietary process results in what Grafoid regards as a new global standard for economically scalable, high-purity graphene products — trademarked under the MesoGraf™ trade name — that can be tailored to both industrial and commercial applications.

Investor Contact:

Scott Anderson

Investor Relations

Phone:  (858) 229-7063

Email:  sanderson@nextcap-ir.com

Grafoid Inc. Announces Retirement of CEO and Succession Plan


Grafoid Inc. Announces Retirement of CEO and Succession Plan

KINGSTON, ONTARIO, July 29, 2020 – Grafoid Inc. (“GRAFOID” or the “Company”), a global leader in the graphene products and applications market, announced today that Gary Economo, President and Chief Executive Officer, advised the Company that he will retire as President and CEO effective July 30, 2020.  Following his retirement, Mr. Economo will continue to serve as a director of the Company and will be available to provide ongoing input and support with respect to the Company’s current and future graphene-based projects and applications.  The Board of Directors has commenced a search for a new President and CEO who has the expertise and track record to lead the company through the next phase of development.

Mr. Jeffrey York, Chairman of the Board stated, “On behalf of the Board of Directors, we would like to thank Gary for his leadership and outstanding achievements in conducting highly successful product launches and corporate development initiatives.  We congratulate Gary for his success and valuable contributions to Grafoid and look forward to hiring a new CEO to Grafoid to continue the ongoing growth and shareholder value creation as we embark on the next stages of product development.”

Mr. Economo, President and CEO commented, “I wish to thank the Board of Directors, management, employees and our dedicated shareholders for all of the support you have provided to me.  I remain confident in the great potential and future of Grafoid’s products and I believe this is the ideal time for me to step aside and allow my successor to continue Grafoid’s product development of graphene-based products.”

About Grafoid

Founded in 2011, Grafoid Inc. is a graphene research, development and investment company that invests in, manages and develops markets for processes that produce economically scalable graphene for use in graphene development applications by leading corporations and institutions. Grafoid’s leading investment produces application friendly, minimal-defect, high-energy density few layer graphene, utilizing a safe, non-destructive extraction process, leaving the lowest possible ecological footprint. The completely unique, proprietary process results in what Grafoid regards as a new global standard for economically scalable, high-purity graphene products — trademarked under the MesoGraf™ trade name — that can be tailored to both industrial and commercial applications.

Investor Contact:

Scott Anderson

Investor Relations

Phone:  (858) 229-7063

Email:  sanderson@nextcap-ir.com

Grafoid Corporate Update- August


Dear Friends and Shareholders,

Our primary focus at Grafoid has been to develop and market our MesografTM-based graphene technology and products to our partners and customers, based on the innovation that is produced in our design labs and through our proprietary engineering processes.  2018 and early 2019 have represented extraordinary progress in this respect and we continue to believe Grafoid is at the forefront of the graphene technology breakthrough.  

Our mission is to become the world’s leading company in graphene research, development and as a company that invests in products to expand the commercialization and economic viability, functionality and technology improvements to foster growth and expand this important industry.  Grafoid’s financial and scientific advancement approach has produced a patent-pending process for large-scale extraction and the associated have volume production of near pristine, low-later graphene, which is sourced directly from undeveloped graphite ore, leaving a very low carbon footprint and ecological impact. 

Grafoid has a highly focused business model and direct strategy to foster corporate growth and return value to shareholders.  Through royalty revenue recognition from our customers based on our proprietary technologies that are in development in the R&D Labs of Grafoid and our partners, we expect to generate significant revenue in th coming years.  Second, we plan to license the rights of our products and technologies, based on MesografTM, through individual or packaged applications through one-time, upfront payments and through longer-term licensing agreements.  We may also seek royalty bearing agreements in which a customer would compensate Grafoid for the use of MesografTM, technology to ensure a constant revenue stream for many years to come.  Finally, we may also sell MesografTM-based products and solutions directly to our joint venture partners.  

Continued Advancement of Revotionary, Proprietary Products

We have made considerable advancement in the in-house development of graphene-based products.  In February of 2019, we officially announced the worldwide launch of an innovative suite of oxidized graphene products, titled GNOXTM.  The GNOXTM  product line represents highly customizable graphene products for an industry currently valued at $50-100M with a compound yearly growth of 40%.  Demand for rapid and massive-scale production remains high for graphene-based materials. Graphene oxide is a single-atomic layered material, made by the powerful oxidation of graphite. Relatively low cost and abundant, it is an oxidized form of graphene, laced with oxygen-containing groups that is easy to process because it is dispersible in water and other solvents.  Customer response to this product line has been outstanding and we are constantly developing new processes to make our graphene oxide materials at commercial scale. We are always striving to reduce environmental impact of our methods without compromising product quality.  

In May of 2019, we announced the official launch of Grafprint3D Inc., a new company with a portfolio of products and solutions to focus on the worldwide additive manufacturing and 3D printing market based on Grafoid’s proprietary MesografTM technology.  Our engineering and R&D Teams have worked exceptionally diligent on the rollout of this product for the global 3D print market.  Grafprint3D Inc. provides its customers with a revolutionary platform for creation of 3D printable materials that will be utilized to enhance a variety of products and applications for markets including direct ink writing, inkjet printing, screen printing, and more.  The initial key application target markets include wearable device fabrication with biocompatible polymers, biomaterial substrates for cell therapy engineering research, and rapid product prototyping with printable advanced nanomaterials. 

Finally, in September 2018, Grafoid announced a strategic partnership with Liquinex, a company specializing in wastewater engineering needs, to provide commercial scale water treatment solutions using Grafoid’s revolutionary and innovative MESOGRAF™ graphene-based filtration technology.  GPURE’s graphene based filtration products are readily scalable to meet these commercial demands making them ideal for industrial level, niche applications such as the concentration of beverages, treatment of crude oil/water mixtures, biofuel and industrial wastewater treatments where reverse osmosis (RO) is not suitable due to the fouling tendencies when concentrated liquids are purged through RO cartridges.

Grafoid has been delivering innovations that represent potential advancements for the industry on a whole.  We believe that the applications that Grafoid and the graphene industry includes:  Plastics and polymers, medical applications, coatings, the renewable and traditional energy markets, computers and electronics, water supply, communications, the construction industry, coatings and lubricants, the automotive and aerospace industries, marine applications, chemicals, manufacturing, safety and environmental, military and defense, food production, the 3D printing market among others.  We are well positioned to capitalize on the growth in these markets from the leadership and engineering teams we have formed. 

Additions to Management Team and Board of Directors

The composition of the Executive and Operational Management Teams was significantly strengthened in 2018.  In September, Grafoid announced the addition of Dr. Michael E. Shannon M.A., M.Sc., M.D. to its Advisory Board where he will draw on his extensive experience developing bio-medical applications – from inception to national deployments – to lend insight and guidance on Grafoid’s portfolio of bio-medical applications and systems. Having received a medical degree from Queen’s University in Canada, which included advanced training in surgery and sports medicine, Dr. Shannon also holds post-graduate degrees in neurochemistry and physiology. He has been actively engaged in applied medical research within these areas for over 27 years.

In Summary

The Company’s focus on enhancing shareholder value is the driving force behind this Management Team and Board of Directors and the potential shareholder value of our development projects and the graphite applications market has only just begun to be explored.  The global graphene industry continues to evolve and become more prominent in the world and we firmly believe that we are at the forefront of this revolution.

The near-term objectives of the Company are to: 

  •  Continue to partner with the most desirable companies in the space, in order to further advance and commercialize graphene, market and sell graphene solutions to generate revenue and enhance value to shareholders.
  •  Enhance our portfolio of high-quality, value-added graphite products and solutions.
  •  Continue to diversify the customer base for our graphite products by geography and market segment, as project development continues and successful customer qualification is completed.
  •  Leverage our relationships with industry partners to promote and increase adoption of our unique, proprietary, single-step process to produce economically and commercially scalable graphene and MesografTM -based products and applications.  

The Team is incredibly focused on delivery of our objectives in project development, superior innovation, future production from our development assets and the maintenance of a manageable cost structure.  

The Board of Directors and Management Team of Grafoid are extremely focused on the execution of our goals of future production, costs, and further project development.  I would like to take this opportunity to thank our shareholders, employees and all stakeholders for their support during 2018 and 2019, and I look forward with great optimism to the Company’s future development and to providing updates on our progress throughout 2019.

Thank you.

Gary Economo,

President and Chief Executive Officer

GRAFOID and Structur3D Sign MOU to Advance and Enable New Market Opportunities in the 3D Printing Market


OTTAWA, ONTARIO, June 25, 2019 – Grafoid Inc. (“GRAFOID” or the “Company”), a global leader in the graphene products and applications market, announced today that it has signed a memorandum of understanding (MOU) with Structur3D Printing Inc. to collaborate and co-market each company’s respective product portfolios to advance and expand product offerings for the global 3D printing market.

Under the terms of the agreement, Grafprint3D Inc., the 3D printing materials division recently launched by Grafoid, and Structur3D will form a partnership to offer customers the opportunity to utilize an innovative, turnkey solution to print graphene-enhanced paste materials, manufactured by Grafprint3D, on the Discov3ry platform of extruders created by Structur3D Printing. 

Grafprint3D has initially launched two product collections for its available types of graphene-enhanced pastes: the MP-LEX and MC-LEX product collections.  Both MP-LEX and MC-LEX feature the environmentally friendly biopolymers PLGA and cellulose, respectively, which are prepared with a formulation of MesografTM sourced exclusively from Grafoid Inc. in order to enhance the electrical and thermal conductivity properties, and mechanical features (tensile, flexural modulus) of the polymer upon curing of the paste into a printed object.

“This partnership between Grafprint3D and Structur3D will provide world-leading companies and research institutions the opportunity to access an easy-to-use paste extrusion printing platform and suite of compatible graphene-enhanced material for their device prototyping and research programs,” commented Gary Economo, CEO of Grafoid.  

“The signing of this MOU is an exciting initial step of our shared goal to help fast-track the prototyping of the next generation of graphene-enhanced products and applications for the 3D printing market,” said Charles Mire, CEO of Structur3D Printing.

Key products developed by our customer base may include: enhanced strength footwear components, glasses frames & eyewear parts, cellphone & tablet cases, EMI shielding devices, biosensors, conductive tissue engineering scaffolds, and implantable devices.

The MOU is non-binding on the parties, and actual terms of any definitive agreement may differ from the terms of the MOU.

For product, sales and more information, please visit the Grafprint3D website at:  www.grafprint3d.com or the Structur3D Printing website at:  www.structur3d.io.  

About Grafoid

Founded in 2011, Grafoid Inc. is a graphene research, development and investment company that invests in, manages and develops markets for processes that produce economically scalable graphene for use in graphene development applications by leading corporations and institutions. Grafoid’s leading investment produces application friendly, minimal-defect, high-energy density few layer graphene, utilizing a safe, non-destructive extraction process, leaving the lowest possible ecological footprint. The completely unique, proprietary process results in what Grafoid regards as a new global standard for economically scalable, high-purity graphene products — trademarked under the MesoGraf™ trade name — that can be tailored to both industrial and commercial applications.

About Grafprint3D Inc.

Grafprint3D (GP3D) Inc. is a new company with a portfolio of products and solutions to focus on the worldwide additive manufacturing and consumer 3D printing market based on Grafoid’s proprietary MesoGrafTM technology. Grafprint3D Inc. provides its customers with a revolutionary platform for creation of 3D printable materials that will be utilized to enhance a variety of products and applications for markets including direct ink writing, inkjet printing, screen printing, and more.  The initial key application target markets include wearable device fabrication with biocompatible polymers, biomaterial substrates for cell therapy engineering research, and rapid product prototyping with printable advanced nanomaterials. 

About Structur3D Printing Inc.

Structur3D Printing (hello@structur3d.io) is a market leader for soft materials printing. Based in Kitchener, Ontario, the company continues to extend the boundaries of 3D printing with soft materials. Its customers include many of the world’s high-ranking universities, government and military research labs, and Fortune 500 research divisions.

Grafoid Inc. Contact:
Gary Economo
Chief Executive Officer
tel: 613-447-8521
email: geconomo@grafoid.com

www.grafoid.com

Structur3D Printing Inc. Contact:

Charles Mire

Chief Executive Officer

tel:  888-407-5888

email:  charles@structur3d.io

www.structur3d.io

GRAFOID Announces the Official Launch of Grafprint3D to Focus on the Worldwide 3D Printing Market


OTTAWA, ONTARIO, May 21, 2019 – Grafoid Inc. (“GRAFOID” or the “Company”), a global leader in the graphene products and applications market, is pleased to announce the worldwide launch of Grafprint3D (GP3D) Inc., a new company with a portfolio of products and solutions to focus on the worldwide additive manufacturing and 3D printing market based on Grafoid’s proprietary MesoGrafTM technology.

Grafprint3D Inc. provides its customers with a revolutionary platform for creation of 3D printable materials that will be utilized to enhance a variety of products and applications for markets including direct ink writing, inkjet printing, screen printing, and more.  The initial key application target markets include wearable device fabrication with biocompatible polymers, biomaterial substrates for cell therapy engineering research, and rapid product prototyping with printable advanced nanomaterials.  

“We are extremely excited to launch Grafprint3D Inc. and to be entering the additive manufacturing & consumer 3D printing materials market. We believe our proprietary portfolio of MesoGraf TM-based products will be well received by our customer base,” commented Gary Economo, CEO of Grafoid.  “Grafoid and Grafprint3D will continue to collaborate and evolve our product offerings to meet and exceed the expectations of our customers, as we seek to grow and diversify our revenue base.”

The global 3D-printed composite materials market is expected to achieve a CAGR of approximately 38% during the time period 2019-2023, led by the consumer electronics, medical and aerospace and automotive sectors, according to a recent report by Technavio.

For product, sales and more information, please visit the Grafprint3D website at:  www.grafprint3d.com.

About Grafoid

Founded in 2011, Grafoid Inc. is a graphene research, development and investment company that invests in, manages and develops markets for processes that produce economically scalable graphene for use in graphene development applications by leading corporations and institutions. Grafoid’s leading investment produces application friendly, minimal-defect, high-energy density few layer graphene, utilizing a safe, non-destructive extraction process, leaving the lowest possible ecological footprint. The completely unique, proprietary process results in what Grafoid regards as a new global standard for economically scalable, high-purity graphene products — trademarked under the MesoGraf™ trade name — that can be tailored to both industrial and commercial applications.

Contact:
Gary Economo
Chief Executive Officer
tel: 613-447-8521
email: geconomo@grafoid.com
www.grafoid.com

GRAFOID is Pleased to Announce the Worldwide Launch of its Innovative Suite of Oxidized Graphene Products – GNOX™


OTTAWA — Grafoid Inc. (“GRAFOID”) is pleased announce the worldwide launch of innovative suite of Oxidized Graphene products – GNOX™. The GNOX™ product line represents highly customizable graphene products for an industry currently valued at $50-100M with a compound yearly growth of 40%.

Demand for rapid and massive-scale production remains high for graphene based materials. Graphene oxide is a single-atomic layered material, made by the powerful oxidation of graphite. Relatively low cost and abundant, it is an oxidized form of graphene, laced with oxygen-containing groups that is easy to process because it is dispersible in water (and other solvents). However, its practical application across various industries has been severely limited due to the impurity and lack of consistency of the current Graphene Oxide available in the marketplace. 

Grafoid’s GNOX™ represents a new standard for Graphene Oxide materials by employing unique methods that ensure a superior level of purity and consistency for customers. Grafoid removes much of the quality uncertainties that have plagued customers of Graphene Oxide in the past. Grafoid believes that the immediate availability of its 3 product skews: UGO-Aerogel, UGO-H2O Dispersion and UGO – Organic Solvent online represents a watershed moment for establishing a quality standard for the purity and consistency of Graphene Oxide products in the Graphene industry. 

Gary Economo, CEO of Grafoid acknowledged the potential to reshape the level of expectations that customers for Graphene Oxide products currently have by stating “Many of the challenges in realizing the full potential of Graphene’s revolutionary applications across various industries is hindered by the lack of quality source graphene to execute. We believe that the overall purity, our multiple processing methodology and ability to customize the material output based on a customer’s needs will empower more innovation and help the Graphene industry on a whole.” 

Grafoid has launched its direct to consumer website at http://gnox.ca online and is announcing the global availability of its innovative Graphene Oxide products at the Graphene for US conference in New York, Feb 14&15, 2019  (http://www.grapheneforus.com/2019/). 

1https://www.nature.com/articles/s41598-017-04139-0* June 20, 2017 (Nature Research Journal)

About Grafoid

Founded in 2011, Grafoid Inc. is a graphene research, development and investment company that invests in, manages and develops markets for processes that produce economically scalable graphene for use in graphene development applications by leading corporations and institutions. Grafoid’s leading investment produces application friendly, minimal-defect, high-energy density few layer graphene, utilizing a safe, non-destructive extraction process, leaving the lowest possible ecological footprint. The completely unique, proprietary process results in what Grafoid regards as a new global standard for economically scalable, high-purity graphene products — trademarked under the MesoGraf™ trade name — that can be tailored to both industrial and commercial applications.

Contact:
Gary Economo
Founding Partner and Chief Executive Officer
tel: 613-447-8521
email: geconomo@grafoid.com
www.grafoid.com

Grafoid Announces the Addition of Dr. Michael E. Shannon to its Advisory Board to Provide Insight and Guidance for Bio-Medical Applications and Systems


OTTAWA — Grafoid Inc. (“GRAFOID”) is pleased to announce the addition of Dr. Michael E. Shannon M.A., M.Sc., M.D. to its Advisory Board where he will draw on his extensive experience developing bio-medical applications – from inception to national deployments – to lend insight and guidance on Grafoid’s portfolio of bio-medical applications and systems. Having received a medical degree from Queen’s University in Canada, which included advanced training in surgery and sports medicine, Dr. Shannon also holds post-graduate degrees in neurochemistry and physiology. He has been actively engaged in applied medical research within these areas for over 27 years.

As a member of the Canadian Forces for 31 years, Dr. Shannon retired at the rank of Commodore (Brigadier General equivalent) as Deputy Surgeon General for Canada. He also served as the senior medical liaison officer for all of the Canadian forces during the first Gulf War.

In 1996 he assumed responsibilities within Health Canada for re-organizing the Canadian blood system. Working with both the provincial and federal governments he oversaw the development of a new corporate entity dedicated exclusively to the management of blood services in Canada. He was then appointed Director General for the Laboratory Centre for Disease Control, a position he held for three years.

In December 2000, Dr. Shannon left the Canadian Federal Government to pursue a new career in industry. In that capacity he simultaneously directed several phase III clinical trials in Canada, the United States and Great Britain for an artificial blood substitute product. Following completion of that work he was asked to accept a special two year assignment with the Canadian Federal Government Auditor General’s office. As Senior Medical Advisor and Audit Principal, his assignment was  to conduct a cost benefit analysis of all government sponsored pharmacare programs and make recommendations directly to the Parliament of Canada. His assignment and presentation to Parliament was completed in November 2004.

Dr. Shannon was then asked to assist the Canadian Public Health Agency (Center for Disease Control equivalent in the United States) as Senior Medical Advisor to the Agency. His responsibility was to direct the rebuilding of the Emergency Medical Response Capacity for Canada. In this regard and under his direction, the largest emergency medical response exercise in the history of the country, involving the overnight construction of a mobile hospital, hundreds of doctors and thousands of patients, was successfully held in Toronto in December of 2007.

Dr. Shannon has been actively engaged in medical bio-oxidative (O3 based) research since 1987 and was directly responsible for the first human clinical trial to have ever been approved in North America which examined the efficacy of O3 delivered via minor autohemotherapy in the treatment of AIDS. He was also responsible for several primate studies utilizing O3 involving scientists from various departments within the Canadian Federal Government including the Animal Disease Research Institute, as well as senior investigators from Cornell University.

Dr. Shannon has served as the Senior Medical Advisor to Medizone International since 2004. In August of 2008 he accepted a position on the Board of Directors of Medizone International and assumed responsibility for medical affairs. In October 2009, he was additionally appointed the President of the Canadian Foundation for Global Health.

With great enthusiasm, Dr Shannon assumes an active role as the medical advisor on an exciting new anti-microbial program at Grafoid. In addition, he will share insight and guidance on a number of other high-growth biomedical applications such as antimicrobial coatings, composite materials for implants, exo-skeleton applications, drug delivery systems technology, water filtration and gas systems and bio-medical devices. “The term innovation is vastly over used these days” stated Dr Shannon, “What I have seen of these new Grafoid developments however,  challenges one’s imagination in terms of trying to fully appreciate their potential impact on this world. Suffice it to say that they are all potential game changers and I am honoured to have the opportunity to contribute”

Gary Economo, CEO of Grafoid shares his outlook on Dr. Shannon’s involvement stating that, “The ability of a company to produce the disruptive products that will shape tomorrow is directly impacted by its ability to effectively draw on the knowledge and learnings that inform today. We’re extremely excited to have access to a true pioneer in Dr. Shannon and look forward to his guidance as we build out our vision for graphene based bio-medical applications.”

About Grafoid.

Founded in 2011, Grafoid Inc. is a graphene research, development and investment company that invests in, manages and develops markets for processes that produce economically scalable graphene for use in graphene development applications by leading corporations and institutions. Grafoid’s leading investment produces application friendly, minimal-defect, high-energy density few layer graphene, utilizing a safe, non-destructive extraction process, leaving the lowest possible ecological footprint. The completely unique, proprietary process results in what Grafoid regards as a new global standard for economically scalable, high-purity graphene products — trademarked under the MesoGraf™ trade name — that can be tailored to both industrial and commercial applications.

Contact Information

Grafoid Inc.
Gary Economo
Founding Partner and Chief Executive Officer

tel: 613-447-8521
email: geconomo@grafoid.com
www.grafoid.com

Liquinex and Grafoid Team Up to Provide Water Purification Solutions Using the Industry Leading MESOGRAF™Graphene Based Filtration Technology – GPURE


OTTAWA — Grafoid Inc. (“GRAFOID”) is pleased announce the strategic partnership with Liquinex, a company specializing in waste water engineering needs, to provide commercial scale water treatment solutions using Grafoid’s innovative MESOGRAF™ graphene based filtration technology.

The increasing demand for clean drinking water, rising scarcity of water resources, rapid industrialization, and increasing construction activities represent real-world factors that necessitate the need for scalable water treatment solutions around the globe.

Compounded by other factors, such as the increased support from government regarding treatment and proper disposal of water, the global market for water treatment solutions is expected to grow at an annual compounded growth rate of 7.4% from 2017 to 20271.

GPURE’s Graphene based filtration products are readily scalable to meet these commercial demands making them ideal for industrial level, niche applications such as the concentration of beverages, treatment of crude oil/water mixtures, biofuel and industrial wastewater treatments where reverse osmosis (RO) is not suitable due to the fouling tendencies when concentrated liquids are purged through RO cartridges.

Conventional filtering materials (e.g. activated carbon, zeolites, flocculants etc.,) have certain limitations of pH-sensitivity, poor efficiency and recoverability to treat a mixture of wide variety of contaminants present in the wastewater. In contrast, MESOGRAF™ graphene, being a 2D-material with high surface-area and functional-group tunability, exhibits outstanding adsorption and recyclability capabilities for a wide variety of contaminants.

Dr. Kiran Manga, Grafoid’s Engineering Manager states: “Our MESOGRAF™ surface engineered graphene derivatives have been successfully deployed to meet the specific requirements (eg. removal of organic dyes from textile and leather industries, phenols and heavy metal ions from ore-processing industry etc.) of our industrial clients. Our GPURE technologies are able to remove up to 99.8% phenol contaminants, 99% dye removal from real-time industrial wastewater samples at neutral pH and room temperature.”

Bashir Ahmad, CEO of Liquinex Group Pte Ltd. confirmed the significance of the strategic partnership with Grafoid as a critical component to a successful roll-out by commenting, “Effective water treatment solutions require strong partnerships and alignment between both public sector, such as IPI Singapore, and private organizations to implement broad based adoption of innovative technologies – such as Grafoid – will be critical.  We are empowered by this partnership with Grafoid and foresee tremendous potential.

Gary Economo, CEO of Grafoid acknowledged the potential global impact of the partnership with Liquinex, observing that  “We know that water is an integral part of many industrial processes and increasing demand for water for industrial uses will result from increasing economic activity. We believe that our GPURE technology can play a critical role in securing the future of water treatment around the globe.”

1 https://globenewswire.com/news-release/2018/06/05/1517364/0/en/Water-Treatment-Market-Poised-to-Register-7-4-CAGR-through-2027.html* Apr 26, 2018 (marketresearch.biz via COMTEX)

About Grafoid.

Founded in 2011, Grafoid Inc. is a graphene research, development and investment company that invests in, manages and develops markets for processes that produce economically scalable graphene for use in graphene development applications by leading corporations and institutions. Grafoid’s leading investment produces application friendly, minimal-defect, high-energy density few layer graphene, utilizing a safe, non-destructive extraction process, leaving the lowest possible ecological footprint. The completely unique, proprietary process results in what Grafoid regards as a new global standard for economically scalable, high-purity graphene products — trademarked under the MesoGraf™ trade name — that can be tailored to both industrial and commercial applications.

About Liquinex.

Located in Singapore, Liquinex is a global manufacturing, design and engineering company using next generation graphene based filters, ceramic membrane and proprietary membrane cleaning technology in the manufacturing of water treatment systems for industrial, municipal water purification and remediation applications. With registered patents for a specialized industrial Cooling Tower/Chilled Water Treatment System, Liquinex provides innovative environmental engineering, services and purification systems. With successful installations in place across Asia including Singapore, Malaysia, Laos and Indonesia – Liquinex continues to commercialize their cutting edge water treatment solutions systems for treating river, underground (well) and various sources of water including industrial waste water for the purpose of removing heavy metals for potable use, recycling or discharge, or meeting regulatory standards. Liquinex has developed a state of the art compact water purification system that weighs under 30Kg, is battery and/or Solar operated, is able to produce up to 500 litres per hour and can be transported as standard luggage check-in on any airline.

Contact Information

Grafoid Inc.

Gary Economo

Founding Partner and Chief Executive Officer

613-447-8521

geconomo@grafoid.com

www.grafoid.com

Grafoid Announces the Appointment of Dr. Vassilis G. Keramidas as Technical Advisor and Intellectual Property Asset Manager


OTTAWA – Grafoid Inc., a global leader in industrial scale graphene application development, is pleased to announce the appointment of Dr. Vassilis G. Keramidas as Technical Advisor with responsibilities for managing its Intellectual Property Assets. His appointment is effective October 3, 2017.

Dr. Keramidas holds Bachelor’s Degrees in Physics and Electrical Engineering, a Master’s Degree in Physics, and a Ph.D. in Solid State Science (Applied Physics).

A renowned scientist and consultant for some of the world’s leading corporations, Dr. Keramidas has extensive experience in guiding the development of new technologies, and the transferring of technologies from the research stage to production.

He is currently the Managing Director of Keramidas International Associates LLC., a firm he founded in 2003, which provides consulting services in: (a) strategic research planning and technology commercialization projects, and (b) the generation, management, commercialization and disposition of Intellectual Property. 

Dr. Keramidas began his career at Bell Laboratories in 1973, where, as a member of the technical staff and as Director, he made substantive materials and device contributions in projects related to the emergence and growth of fiber optics communications. Upon the breakup of the Bell System, in 1984, he joined Bell Communications Research (Bellcore), as a founding member. He served there as Director and Executive Director from 1984 to 1997, and as Vice President of Formative Technologies from 1997 to 2003, all in the applied research area.

For his contributions and technical leadership in his field, Dr. Keramidas has
been elected a Fellow of the Institute of Electrical and Electronic Engineers.

In 1995, following his impressive technical career, he focused his attention to the challenging field of commercialization of Intellectual Property assets. He founded a P&L entity within Bellcore and launched the Intellectual Property Commercialization program of IP assets. He started with IP assets invented in his own divisions and later expanded his efforts to a number of Bellcore and Telcordia invented technologies, bringing millions of dollars in revenue via worldwide licensing programs, patent sales, spin-offs, equity investments in start-ups and patent donations. The pioneering Bellcore Plastic Lithium-ion (PLiON) Battery Technology alone, invented in his Division, was licensed to 22 Corporations worldwide in Asia and Europe.

Among his many corporate affiliations, Dr. Keramidas has served as a director of Twenty First Century Battery Ltd., of India. He is also on the Board of Pleiades Battery Research Inc., with R&D facilities in China, and is Chairman of the Board of Valence Technologies Inc., a global leader in the development and manufacture of intrinsically safe, long-life lithium iron magnesium phosphate (LiFeMgPO4) advanced energy systems.

“The addition of Dr. Keramidas to our management team comes at a pivotal time for Grafoid as we move toward the commercialization of our next generation graphene energy, graphene coatings and graphene polymer applications,” said Gary Economo, Grafoid CEO and Founding Partner. 

“His skills, global experience, expertise and history dovetail with our expansionary business development and commercialization agenda,” Mr. Economo said. “We are very fortunate to have Dr. Keramidas advising our management team.”

About Grafoid Inc. 

Grafoid is a privately owned, global graphene application development and technology licensing company, focused on the commercialization of its novel Mesograf™, Grafenex and GPURE product innovations for next generation energy applications, composites, coatings and membranes for industrial applications.

The company provides expertise as well as product and processes for transformative, industrial-scale graphene applications in partnership with leading corporations and institutions around the world.

A Canadian corporation, founded in 2011, Grafoid invests in graphene applications and economically scalable production processes for graphene and graphene derivatives from raw, unprocessed graphite ore. Focus Graphite Inc. holds a significant interest in Grafoid Inc.

Grafoid’s research is supported through the Industrial Research Assistance Program (IRAP) of the National Research Council of Canada, and, on February 20, 2015, Grafoid received an $8.1 million investment from the SD Tech Fund™ of Sustainable Development Technology Canada (SDTC) to develop a technology that will automate Mesograf™ graphene production and end-product development. SDTC is mandated by the Government of Canada to support clean technology companies as they move their technologies to market.

For more information about Grafoid, please visit http://www.grafoid.com

Contact:

Mr. Gary Economo
Chief Executive Officer and Founding Partner
+1 613-238-7417
geconomo@grafoid.com